Aligos Therapeutics (ALGS)
(Delayed Data from NSDQ)
$0.78 USD
-0.04 (-4.40%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $0.79 +0.01 (1.02%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ALGS 0.78 -0.04(-4.40%)
Will ALGS be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ALGS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALGS
Aligos Therapeutics, Inc. (ALGS) Just Flashed Golden Cross Signal: Do You Buy?
Certara, Inc. (CERT) Lags Q4 Earnings Estimates
ALGS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Aligos Therapeutics (ALGS) Stock Outpacing Its Medical Peers This Year?
Aligos Therapeutics, Inc. (ALGS) Reports Q1 Loss, Lags Revenue Estimates
Aligos Therapeutics, Inc. (ALGS) Reports Q4 Loss, Tops Revenue Estimates
Other News for ALGS
Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study
Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD
Aligos Therapeutics mourns passing of advisor Stephen Harrison
Aligos Therapeutics to present data on ALG-097558 at ESCMID
Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024